system have never been greater. Patients with Parkin son's disease have received implants of both human fe tal embryonic tissue and porcine fetal tissue in an effort to replace lost and degenerating dopaminergic tissue (2, 10) . Early clinical trials of cell transplantation have commenced for patients with Huntington's disease (5) .
Allogeneic adrenal chromaffin tissue has been implanted in cancer patients suffering from intractable pain (8) .
Polymer encapsulated cells genetically modified to se crete human ciliary neurotrophic factor (CNTF) have been implanted in the lumbar dural space in patients with amyotrophic lateral sclerosis (motor neuron dis ease) (1) . Trials of cell transplantation in patients with focal striatal ischemic injury are also being evaluated and preliminary results are eagerly awaited. At the pre clinical level studies are evaluating the potential of cell implantation strategies in patients with multiple sclerosis and spinal cord injury (4, 9) .
These early trials are based on a large body of basic scientific and preclinical data that has been constantly evolving since the early studies of neural grafting in ani mal models of neurodegenerative disease. The develop ment of this field is the result of close integration be tween laboratory and clinical studies and underlines the role of a multidisciplinary approach to developing novel strategies to treat neurological disease. The basic sci entific data have been reviewed extensively (3), but rela tively little attention has been paid to reviewing the clin ical data across the broad spectrum of neurological disease in which cell transplantation has played a role.
Cell Transplantation
for Neurological Disorders does just this and is an exciting and stimulating review of much of the field. was relatively short (7) . Further studies in larger series are therefore essential before firm conclusions concern ing the therapeutic applicability of neural grafting in HD can be drawn. 
